Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents
- PMID: 10537360
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents
Abstract
Previously we showed that a mismatch repair (MMR)-deficient cell line, HCT116 (hMLH1 mut), unlike a MMR wild-type cell line, SW480, was more resistant to the therapeutic methylating agent, temozolomide (TMZ), because the MMR complex fails to recognize TMZ-induced O6-methylguanine DNA adduct mispairings with thymine that arise after replication. TMZ also produces N7-methylguanine and N3-methyladenine adducts that are processed efficiently by the base excision repair (BER) system. After removal of the methylated base by methylpurine glycosylase, which creates the abasic or apurinic-apyrimidinic (AP) site, the phosphodiester bond is hydrolyzed immediately by AP endonuclease, initiating the repair of the AP site. Methoxyamine (MX) reacts with the abasic site and prevents AP endonuclease cleavage, disrupting DNA repair. MX potentiated the cytotoxic effect of TMZ with a dose modification factor (DMF) of 2.3+/-0.12 in SW480 and 3.1+/-0.16 in HCT116. When combined with O6-benzylguanine (BG), MX and TMZ dramatically increased TMZ cytotoxicity (65.8-fold) in SW480, whereas no additive effect was seen in HCT116. This suggests that N7-methylguanine and N3-methyladenine adducts are cytotoxic lesions in MMR-deficient and wild-type cells when BER is interrupted. Because poly(ADP-ribose) polymerase (PARP) aids in processing of DNA strand breaks induced during MMR and BER, we asked whether PARP inhibitors would also affect BER-mediated cell killing. We found that PARP inhibitors PD128763, 3-aminobenzimide, and 6-aminonicotinamide increased the sensitivity to TMZ in both HCT116 MMR-deficient cells and SW480 MMR wild-type cells. In HCT116 cells, PD128763 remarkably decreased resistance to TMZ, with a DMF of 4.7+/-0.2. However, the combination of PD128763, BG, and TMZ had no greater effect, indicating that persistent O6-methylguanine had no effect on cytotoxicity. In SW480, the DMF for TMZ cytotoxicity was 3.1+/-0.12 with addition of PD128763 and 36 with addition of PD128763 and BG. Synergy analysis by median effect plots indicated a high degree of synergy between TMZ and MX or PD128763. In contrast, 1,3-bis(2-chloroethyl)-1-nitrosourea combined with either MX or PD128763 showed little if any potentiation observed in the absence of BG in either cell line, suggesting that BER pathway has little impact on cytotoxic processing of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced adducts. These studies indicate that targeting BER with MX or PARP inhibitors enhances the cytotoxicity of methylating agents, even in MMR-deficient cells.
Similar articles
-
Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells.Mutat Res. 2001 May 10;485(4):269-81. doi: 10.1016/s0921-8777(01)00076-3. Mutat Res. 2001. PMID: 11585361
-
Base excision repair as a therapeutic target in colon cancer.Clin Cancer Res. 2002 Sep;8(9):2985-91. Clin Cancer Res. 2002. PMID: 12231545
-
Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.Cancer Res. 1996 Dec 1;56(23):5375-9. Cancer Res. 1996. PMID: 8968088
-
Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway.Curr Opin Investig Drugs. 2004 Jun;5(6):623-7. Curr Opin Investig Drugs. 2004. PMID: 15242251 Review.
-
Triazene compounds: mechanism of action and related DNA repair systems.Pharmacol Res. 2007 Oct;56(4):275-87. doi: 10.1016/j.phrs.2007.08.003. Epub 2007 Aug 9. Pharmacol Res. 2007. PMID: 17897837 Review.
Cited by
-
Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.Clin Cancer Res. 2024 Aug 1;30(15):3167-3178. doi: 10.1158/1078-0432.CCR-23-4098. Clin Cancer Res. 2024. PMID: 38836759 Free PMC article. Clinical Trial.
-
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.Clin Cancer Res. 2007 Apr 1;13(7):2038-45. doi: 10.1158/1078-0432.CCR-06-2149. Clin Cancer Res. 2007. PMID: 17404084 Free PMC article.
-
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.PLoS One. 2020 Feb 26;15(2):e0229534. doi: 10.1371/journal.pone.0229534. eCollection 2020. PLoS One. 2020. PMID: 32101575 Free PMC article.
-
Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma.CNS Oncol. 2021 Sep 1;10(3):CNS74. doi: 10.2217/cns-2021-0002. Epub 2021 Sep 6. CNS Oncol. 2021. PMID: 34486380 Free PMC article.
-
A novel class of chemicals that react with abasic sites in DNA and specifically kill B cell cancers.PLoS One. 2017 Sep 19;12(9):e0185010. doi: 10.1371/journal.pone.0185010. eCollection 2017. PLoS One. 2017. PMID: 28926604 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous